Cargando…
Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel class of glucose-lowering agents that significantly improve the prognosis of patients with type 2 diabetes (T2D) and heart failure. SGLT2i has recently been implicated in the treatment of atrial fibrillation (AF) with clinical data demon...
Autores principales: | Peng, Xiaodong, Li, Linling, Zhang, Mengxia, Zhao, Qianqian, Wu, Kui, Bai, Rong, Ruan, Yanfei, Liu, Nian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417344/ https://www.ncbi.nlm.nih.gov/pubmed/32848857 http://dx.doi.org/10.3389/fphys.2020.00912 |
Ejemplares similares
-
“Pill-in-the-Pocket” Treatment of Propafenone Unmasks ECG Brugada Pattern in an Atrial Fibrillation Patient With a Common SCN5A R1193Q Polymorphism
por: Li, Linling, et al.
Publicado: (2019) -
Sex Differences and Temporal Trends in Hospitalization for Catheter Ablation of Nonvalvular Atrial Fibrillation: A Single-Center Experience for 15 Years
por: Peng, Xiaodong, et al.
Publicado: (2022) -
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013) -
A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
por: Karamichalakis, Nikolaos, et al.
Publicado: (2022) -
Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
por: Chang, Sheng‐Nan, et al.
Publicado: (2023)